Our objective is to discover, develop and commercialize new medicines with superior efficacy, convenience, tolerability and/or safety.
The key elements of our strategy are to:
Apply our expertise in multivalency primarily to validated targets to efficiently discover and develop superior
medicines in areas of significant unmet medical need. Our drug discovery efforts are based on our expertise in
multivalency. Multivalency involves the simultaneous attachment
of a single molecule to multiple binding sites on one or more biological
targets. We believe that by applying our expertise in multivalency
we can discover medicines that will be superior to many market-leading
medicines by substantially improving potency, duration of action
and/or selectivity.
Identify at least two structurally different product candidates in each therapeutic program
whenever practicable. We believe that this can increase the
likelihood of successfully bringing superior medicines to market.
Partner
with global
pharmaceutical
companies to
accelerate development
and commercialization
of our product
candidates. Our
strategy is
to seek collaborations
with leading
global pharmaceutical
companies,
such as GlaxoSmithKline plc, Astellas
Pharma Inc., and AstraZeneca AB
to accelerate
development
and commercialization
of our product
candidate pipeline
at the strategically
appropriate
time.
Leverage
the extensive experience
of our people. We have an experienced senior management team with many years of experience
discovering, developing and commercializing new medicines with companies
such as Bristol-Myers Squibb Company, Gilead Sciences, Inc., GlaxoSmithKline plc, ICOS Corporation, Merck & Co., Millennium Pharmaceuticals, Inc., and Pfizer Inc.
Improve, expand and protect our technical capabilities. We have
created a substantial body of know-how and trade secrets in the
application of our multivalency approach to drug discovery. We expect
to continue to make substantial investments in multivalency and
other technologies to maintain what we believe are our competitive advantages in drug discovery.
|